Singapore temporarily halts use of two flu vaccines after S Korea deaths | Inquirer News

Singapore temporarily halts use of two flu vaccines after S Korea deaths

/ 01:04 PM October 26, 2020

FILE PHOTO: A man gets an influenza vaccine at a branch of the Korea Association of Health Promotion in Seoul, South Korea, October 23, 2020. REUTERS/Kim Hong-Ji/File Photo

SINGAPORE — Singapore has temporarily halted the use of two influenza vaccines as a precaution after some people who received them in South Korea died, becoming among the first countries to publicly announce a halt of the vaccines’ usage.

South Korea reported that 48 have died as of Saturday after getting flu shots, but said it would carry on with the state-run vaccination program as they found no direct link between the deaths and the shots.

ADVERTISEMENT

No deaths associated with influenza vaccination have been reported in Singapore to date, but the decision to halt the use of SKYCellflu Quadrivalent and VaxigripTetra was precautionary, the health ministry and the Health Sciences Authority (HAS) said in a statement late on Sunday.

FEATURED STORIES

The HSA is in touch with the South Korean authorities for further information as they investigate to determine if the deaths are related to influenza vaccinations.

SKYCellflu Quadrivalent is manufactured by South Korea’s SK Bioscience and locally distributed by AJ Biologics, while VaxigripTetra is manufactured by Sanofi and locally distributed by Sanofi Aventis.

Two other influenza vaccines that have been brought into Singapore for the Northern Hemisphere 2020/21 influenza season may continue to be used, Singapore health authorities said.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Singapore

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.